Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson’s disease: safety and short-term effects
Objective: In this study, we describe the safety and short-term effects of the first hypoxia-based treatment trial in Parkinson’s disease by deploying a personalized multiple…Integrated safety analysis of BIA-28-6156 phase 1 clinical trials (a novel allosteric activator of beta-glucocerebrosidase)
Objective: To describe the safety profile and tolerability of BIA-28-6156 observed during phase 1 clinical trials. Background: BIA-28-6156 is a novel allosteric activator of beta-glucocerebrosidase…Experiences of People with Parkinson’s Disease use of a wearable technology for the management of drooling; qualitative insights from the Cue Band study
Objective: In the Cue Band study, people with Parkinson’s Disease (PwP) are participating in a randomised controlled trial to compare a mobile Application (App) with…Impact of rs6265 in the Host and Donor on Dopamine Neuron Graft Function.
Objective: Extend investigations into the effect of the rs6265 single nucleotide polymorphism (SNP) on dopamine (DA) neuron graft efficacy using a parkinsonian rat model. Background:…Is there a role for safinamide in atypical parkinsonian syndromes?
Objective: To search for possible benefits of safinamide in atypical parkinsonism. Background: Safinamide is a selective reversible monoamine oxidase-B inhibitor with both dopaminergic and glutamatergic…Neurophysiological and Clinical Effects of Low-intensity Transcranial Ultrasound of the Motor Cortex in Parkinson’s Disease
Objective: Evaluate the neurophysiological and clinical effects of transcranial ultrasound stimulation (TUS) of motor cortex (M1) in PD patients. Background: Low-intensity TUS is a novel,…Longitudinal Program to Prevent PD (LoPP-PD): Multimodal Risk Stratification Informs Personalized Intervention
Objective: Longitudinal evaluation of personalized intervention strategies informed by detailed clinical and laboratory biomarker analysis to reduce relative risk of Parkinson’s disease in first degree…Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques
Objective: To determine whether striatal CaV1.3 gene silencing ameliorates levodopa-induced dyskinesias (LID) in the preclinical gold-standard non-human primate (NHP) model without altering levodopa’s antiparkinsonian benefit.…Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice
Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…Striatal Blood brain barrier opening in Parkinson´s disease
Objective: To test safety and feasibility of repeated low-intensity focused ultrasound (FUS) blood brain barrier opening (BBB) in the striatum of Parkinson’s disease (PD) patients.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 11
- Next Page »